RT Journal Article
SR Electronic
T1 Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1801470
DO 10.1183/13993003.01470-2018
A1 Lei Gao
A1 Haoran Zhang
A1 Henan Xin
A1 Jianmin Liu
A1 Shouguo Pan
A1 Xiangwei Li
A1 Ling Guan
A1 Fei Shen
A1 Zisen Liu
A1 Dakuan Wang
A1 Xueling Guan
A1 Jiaoxia Yan
A1 Hengjing Li
A1 Boxuan Feng
A1 Xuefang Cao
A1 Yu Chen
A1 Wei Cui
A1 Zongde Zhang
A1 Yu Ma
A1 Xiaoyou Chen
A1 Xinhua Zhou
A1 Qi Jin
A1 ,
YR 2018
UL http://erj.ersjournals.com/content/early/2018/09/27/13993003.01470-2018.abstract
AB Latent tuberculosis infection (LTBI) management is now a critical component of the End TB Strategy. In this randomised controlled trial (ChiCTR-IOR-15007202), two short-course regimens with rifapentine plus isoniazid, the 3-month once-weekly regimen and the 2-month twice-weekly regimen, were initially designed to be evaluated for 50–70 years aged rural residents with LTBI in China. Due to the fast-growing occurrence of adverse effects, the treatments were early terminated after 8 weeks for once-weekly regimen and after 6 weeks for twice-weekly regimen, respectively. In the modified intention-to-treat analysis on the completed doses, cumulative rate of active disease during 2 years follow-up was 1.21% (14/1155) in the untreated controls, 0.78% (10/1284) in the group of 8-week once-weekly regimen, and 0.46% (6/1299) in the group of 6-week twice-weekly regimen. The risk of active disease was decreased with adjusted hazard ratio of 0.63 (95% CI, 0.27–1.43) and 0.41 (95% CI, 0.15–1.09) for the treatments, respectively. No significant difference was found in the occurrence of hepatotoxicity, 1.02% (13/1279) versus 1.17% (15/1279) (p=0.704). The short regimens tested must be used with caution among elderly because of the high rates of adverse effects. Further work is necessary to test the ultra-short regimens in younger people with LTBI.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Gao has nothing to disclose.Conflict of interest: Dr. Cui has nothing to disclose.Conflict of interest: Dr. Cao has nothing to disclose.Conflict of interest: Dr. Chen has nothing to disclose.Conflict of interest: Dr. Feng has nothing to disclose.Conflict of interest: Dr. Guan has nothing to disclose.Conflict of interest: Dr. Jin has nothing to disclose.Conflict of interest: Dr. Li has nothing to disclose.Conflict of interest: Dr. Liu has nothing to disclose.Conflict of interest: Dr. Ma has nothing to disclose.Conflict of interest: Dr. Pan has nothing to disclose.Conflict of interest: Dr. Shen has nothing to disclose.Conflict of interest: Dr. Wang has nothing to disclose.Conflict of interest: Dr. Zhang has nothing to disclose.Conflict of interest: Dr. Xin has nothing to disclose.